The U.S. Food and Drug Administration announced full approval of lecanemab for early-stage Alzheimer's.
MURRAY — Ren Willie likes to tell simple jokes and sprinkle puns into conversations. Those jokes and puns, he says, are always clean and basically on a junior high level. That makes sense because he was a junior high resource and health teacher for many years.
So he and his wife of 45 years, Jane Willie, were among Alzheimer's patients and their families paying close attention Thursday when the U.S. Food and Drug Administration announced full approval of lecanemab for early-stage Alzheimer's. It's the first drug shown to delay the progression of the disease.
It's not clear that Ren Willie will qualify, and his doctor may not ever prescribe it, the Willies told Deseret News. Or that he would choose to take the drug, which has the potential for significant side effects. But they feel strongly that medications approved by the FDA should be available, the decision between doctor, patient and pocketbook. Those with Alzheimer's typically look to Medicare for help with costs.
Lecanemab is only approved for early Alzheimer's and there have been some side effects reported, including rare but concerning brain bleeds. The drug slows cognitive impairment by about 27%, according to the clinical trials. That raises the specter of a veteran being treated while a spouse in a similar stage of Alzheimer's could be denied the treatment.
But the Willies believe access to the drug was worth rallying around. Once a drug is approved, even in accelerated form, it should be covered, they said.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA to decide on Alzheimer’s drug approvalFull approval would likely prompt the Centers for Medicare and Medicaid Services to change how it covers the drug, broadening access for up to about a million people with early onset Alzheimer’s.
続きを読む »
FDA to decide on Alzheimer’s drug approvalFull approval would likely prompt the Centers for Medicare and Medicaid Services to change how it covers the drug, broadening access for up to about a million people with early onset Alzheimer’s.
続きを読む »
FDA to make a decision on whether to approve first Alzheimer’s drugThe FDA is set to decide whether it will fully approve the first Alzheimer’s drug to show it could slow the disease’s progression in certain patients. But the decision could also have other implications, including who would get access to it.
続きを読む »
New Alzheimer’s drug could save thousands of lives in WashingtonWashington has an estimated 120,000 patients over the age of 65 suffering from Alzheimer's.
続きを読む »
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
続きを読む »
FDA grants full approval to new Alzheimer's drug meant to slow diseaseBREAKING: FDA grants full approval of Alzheimer’s drug Leqembi, amid concerns about its safety, cost and accessibility. The move marks the first time that a drug meant to slow the progression of the disease has been granted full regulatory approval.
続きを読む »